There are 2789 resources available
626P - Estimation of overall survival with subsequent treatment effect by applying inverse probability of censoring weighting in the LATITUDE study
Presenter: Nobuaki Matsubara
Session: ePoster Display
627P - Phase II neoadjuvant trial of the anti–B7-H3 antibody, enoblituzumab, in men with localized prostate cancer: Safety, efficacy and immune correlates
Presenter: Eugene Shenderov
Session: ePoster Display
628P - Universal germline testing of prostate cancer patients: Are genetic testing guidelines an aid or an impediment to precision therapy?
Presenter: Neal Shore
Session: ePoster Display
629P - Patient-reported outcomes in prostate cancer patients receiving PSMA-targeted radionuclide therapy
Presenter: Brian Gonzalez
Session: ePoster Display
630P - Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial
Presenter: Christian Gratzke
Session: ePoster Display
631P - Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration resistant prostate cancer in an open-label phase Ib study
Presenter: Alejo Rodriguez-Vida
Session: ePoster Display
632P - Differential transcriptomic profiling of BCL2-related genes in primary tumor (PT) and metastatic sites (MS) of prostate cancer (PCa)
Presenter: Benedito A Carneiro
Session: ePoster Display
633P - Mutational landscape differences between young-onset and older-onset prostate cancer patients
Presenter: Yong Wang
Session: ePoster Display
585P - Safety analysis of the phase III IPATential150 trial of ipatasertib (ipat) plus abiraterone (abi) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Cora Sternberg
Session: ePoster Display
586P - Safety of tazemetostat (TAZ) in combination with abiraterone/prednisone (A/P) or enzalutamide (E) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: ePoster Display